Avaclyr FDA Approval History
Last updated by Judith Stewart, BPharm on April 3, 2019.
FDA Approved: Yes (First approved March 29, 2019)
Brand name: Avaclyr
Generic name: acyclovir
Dosage form: Ophthalmic Ointment
Company: Fera Pharmaceuticals
Treatment for: Herpes Simplex Dendritic Keratitis
Avaclyr (acyclovir ophthalmic ointment) is a herpes simplex virus nucleoside analog DNA polymerase inhibitor indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.
- Herpetic keratitis is an infection of the cornea that is caused by the herpes simplex virus.
- Avaclyr ophthalmic ointment is applied as a 1 cm ribbon to the inside of the lower lid of the affected eye five times per day until the corneal ulcer is healed, then three times per day for seven days.
- The most common adverse reactions reported in patients using Avaclyr were eye pain (stinging), punctate keratitis and follicular conjunctivitis.
Development timeline for Avaclyr
| Date | Article |
|---|---|
| Apr 1, 2019 | Approval FDA Approves Avaclyr (acyclovir ophthalmic ointment) for the Treatment of Herpetic Keratitis |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
